Allogene Therapeutics Stock In The News

ALLO Stock  USD 1.20  0.04  3.23%   
Our overall analysis of Allogene Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Allogene Therapeutics. The specific impact of Allogene Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Allogene Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Allogene Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Allogene Therapeutics Backtesting and Allogene Therapeutics Hype Analysis.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.

Allogene Therapeutics Today Top News and Investor Outlook

Investing News at Macroaxis
Allogene's SWOT analysis: stock outlook amid clinical delays, promising data
https://www.investing.com/news/swot-analysis/allogenes-swot-analysis-stock-outlook-amid-clinical-delays-promising-data-93CH-4096075
 Bullish
Yahoo News
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
https://finance.yahoo.com/news/why-allogene-therapeutics-allo-52-153006820.html
 Bullish
Macroaxis News: globenewswire.com
Allogene Therapeutics Provides Updated P...
https://www.globenewswire.com/news-release/2025/06/01/3091475/0/en/Allogene-Therapeutics-Provides-Updated-Phase-1-Data-Highlighting-Durable-Responses-with-ALLO-316-in-Heavily-Pretreated-Advanced-Renal-Cell-Carcinoma-at-ASCO.html
 Bullish
seekingalpha News
SA Asks: Which oncology companies are attractive M&A targets?
https://seekingalpha.com/news/4452742-sa-asks-which-oncology-companies-are-attractive-ma-targets?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Bullish
Macroaxis News: globenewswire.com
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
https://www.globenewswire.com/news-release/2025/05/23/3087458/0/en/Allogene-Therapeutics-Announces-Participation-in-Upcoming-Investor-Conferences.html
 Neutral
Macroaxis News: globenewswire.com
Allogene Therapeutics Announces ASCO 202...
https://www.globenewswire.com/news-release/2025/05/22/3087175/0/en/Allogene-Therapeutics-Announces-ASCO-2025-Abstract-Publication-Featuring-Oral-Presentation-of-ALLO-316-in-Kidney-Cancer-and-ALPHA3-TIP-Poster-for-Cema-Cel.html
 Bullish
Yahoo News
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
https://finance.yahoo.com/news/allogenes-q1-earnings-line-estimates-102900829.html
 Neutral
Macroaxis News: globenewswire.com
Allogene Therapeutics to Present Updated...
https://www.globenewswire.com/news-release/2025/04/23/3066562/0/en/Allogene-Therapeutics-to-Present-Updated-ALLO-316-Clinical-Results-in-Kidney-Cancer-in-Oral-Presentation-and-ALPHA3-Trial-in-Progress-Poster-for-Cema-Cel-at-the-2025-American-Socie.html
 Bullish
Macroaxis News: globenewswire.com
Allogene Granted Three U.S. FDA Fast Tra...
https://www.globenewswire.com/news-release/2025/04/07/3056719/0/en/Allogene-Granted-Three-U-S-FDA-Fast-Track-Designations-FTD-for-ALLO-329-a-Next-Generation-Dual-Targeted-CD19-CD70-Allogeneic-CAR-T-for-the-Treatment-of-Lupus-Myositis-and-Scleroder.html
 Neutral
Macroaxis News: globenewswire.com
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
https://www.globenewswire.com/news-release/2025/03/13/3042573/0/en/Allogene-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Business-Update.html
 Bullish

Allogene Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Allogene and other traded companies coverage with news coverage. We help investors stay connected with Allogene headlines for the 26th of June to make an informed investment decision based on correlating the impacts of news items on Allogene Stock performance. Please note that trading solely based on the Allogene Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Allogene Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Allogene Therapeutics investors visualize upcoming and past events in order to time the market based on Allogene Therapeutics noise-free hype analysis.

Allogene Therapeutics Investors Sentiment

The influence of Allogene Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Allogene. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Allogene Therapeutics' public news can be used to forecast risks associated with an investment in Allogene. The trend in average sentiment can be used to explain how an investor holding Allogene can time the market purely based on public headlines and social activities around Allogene Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Allogene Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Allogene Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Allogene Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Allogene Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Allogene Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Allogene Therapeutics' short interest history, or implied volatility extrapolated from Allogene Therapeutics options trading.
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:
Check out Allogene Therapeutics Backtesting and Allogene Therapeutics Hype Analysis.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.22)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.29)
Return On Equity
(0.60)
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.